Genome-wide analysis of ivermectin response by Onchocerca volvulus

The World Health Organization estimates that at least 25 million people are infected with Onchocerca volvulus worldwide, causing blindness or visual impairment in 300,000 and 800,000 people, respectively. Over 120 million people are at risk of infection with the parasite.

Annual or bi-annual mass drug administration (MDA) with ivermectin is the recommended strategy for the control of onchocerciasis. MDA is likely to exert selection pressure on these parasites, and phenotypic and genetic changes in several O. volvulus populations from Cameroon and Ghana—exposed to more than a decade of regular ivermectin treatment—have raised concern that sub-optimal responses to treatment with ivermectin are becoming more frequent and may spread.

In the paper of Doyle and coworkers, the authors compared the genetic diversity between 108 Onchocerca worms isolated from patients from Ghana and Cameroon, with different individual and/or community ivermectin treatment history and different responses to treatment.

Genome-wide analyses revealed genetic variation that significantly differentiated worms isolated from good responders and sub-optimal responders. These genomic differences were not randomly distributed throughout the genomes, but were clustered in 31 loci, with little overlap in position or gene content between countries. Genes previously suggested to be associated with sub-optimal responses to ivermectin were largely absent in the loci.

The authors concluded that ivermectin responses are polygenically-determined quantitative traits, and that identical or related molecular pathways but not necessarily individual genes are likely to determine the ivermectin responses.

Back to news

To improve the user experience on this site we use cookies. I agree